focu double-digit volum growth newli launch product
maintain hold rate upgrad
tp previous tp base
forward price-to-earnings multipl adjust ep
provid upsid potenti
look fundament strong price-to-earnings concern
us would expect move ahead consid growth
earn new product launch strong pipelin
estim base follow factor double-digit
volum growth new recent launch product
includ repatha kyproli prolia xgeva strong
expect launch
revenu increas total
product revenu increas
strong growth revenu due double-digit volum
growth new recent launch product includ
repatha kyproli prolia xgeva
total revenu prolia increas
total revenu xgeva increas
total revenu kyproli increas
total revenu repatha
increas total revenu
blyncyto increas total
revenu increas due higher unit demand higher net
declar dividend per share june
repurchas share
common stock total cost
compani name inc tickeramgnstock ratingholdunchangedindustri viewoverweightpositivepric sep week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc septemb
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
net incom increas
non-gaap net incom increas
ep increas
non-gaap ep increas
may announc ec approv
new indic repatha label adult
june announc ec grant full
market author blincyto may
announc receiv complet respons
letter fda biolog licens applic
kanjinti
launch aimovig
first cgrp inhibitor approv migrain
prevent aimovig also mark first entri
new therapeut area neurosci
remain confid newer product
launch well medicin advanc
pipelin expect revenu rang
 expect non-gaap ep
rang
price-to-earnings volatil past due volatil
stock price price-to-earnings trail
current
price-to-earnings averag price-to-earnings
expect forward price-to-earnings expect top-lin
revenu grow base
product pipelin upcom launch
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date sep ex-dividend date aug last split factor new per last split date inform amgen inc septemb
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg total oper oper interest incom interest incom incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli inc septemb
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in capital- retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item amgen inc septemb
provid oper activ increas compar due
provid invest activ compar cash use invest activ
cash provid invest activ due market secur
billion off-set partial capit expenditur
use financ activ due repurchas common stock
payment dividend repay debt
depreciation- defer incom oper gains- increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate changes- net chang begin end inc septemb
deliv strong result double-digit volume-driven
growth new recent launch product
total revenu increas compar
total product revenu increas compar
due higher unit demand total revenu increas
compar due mileston
payment receiv novarti
gaap cog flat compar previou year
quarter cog product sale decreas pt
compar decreas cog due lower
royalti cost decreas acquisition-rel amort intang
non-gaap cog increas compar
non-gaap cog product sale increas
compar
increas
compar
product sale
increas pt
compar
sg expens increas compar
sg expens product sale increas
pt non-gaap sg expens increas
compar non-gaap sg expens
product sale increas pt compar
increas sg expens due invest product
launch market product support
 expens compar
 expens product sale compar
non-gaap expens compar
non-gaap expens product sale
compar
oper expens decreas compar
due chang fair valu conting consider liabil
relat busi combin lower net charg relat
restructur plan off-set partial expens relat legal proceed
oper expens increas compar
non-gaap oper expens increas
compar total oper expens increas
due invest newer recent launch product expens
categori also reflect save transform process improv
oper margin increas pt compar
non-gaap oper margin compar
tax rate decreas pt compar
non-gaap tax rate decreas pt compar
decreas effect tax rate due
impact tax reform off-set partial prior year benefit
associ effect settlement certain state feder tax
net incom increas compar
non-gaap net incom increas
compar
increas pt
compar
gaap ep increas
compar
gaap ep increas compar
non-gaap ep increas compar
gener free cash flow compar
due higher cash tax result first instal
repatri tax paid partial off-set lower on-going incom tax
liabil well higher net incom declar dividend per
share june
repurchas share common stock
total cost end remain
stock repurchas author
total revenu increas compar
total product sale increas compar
total revenu increas
compar
compar
cog decreas compar
decreas cog due lower royalti cost decreas
acquisition-rel amort intang asset
 expens compar sg
expens compar
expens compar
oper expens increas compar
oper margin compar
total oper expens increas due invest newer
recent launch product expens categori also reflect save
transform process improv effort
tax rate compar decreas
effect tax rate due impact tax reform
off-set partial prior year benefit associ effect settlement
certain state feder tax matter
net incom increas compar
ep increas compar
net incom increas
compar
compar
market six therapeut area cardiovascular neurosci
oncology/hematolog inflamm nephrolog bone health
princip product neulasta enbrel sensipar/mimpara prolia
aranesp xgeva epogen also market number product
parsabiv imlyg corlanor aimovig kanjinti
total product revenu increas compar
due higher unit demand total product sale increas
compar
total product sale compar
total product sale compar
total product sale rest world increas
compar total product sale
rest world increas compar
total revenu prolia increas
compar total revenu increas
compar
total revenu increas
compar total revenu increas
compar
total revenu rest world increas
compar total revenu rest
world increas compar
increas global prolia sale due higher unit demand
higher net sell price
increas
compar
due
total revenu prolia
increas
compar
total revenu xgeva increas
compar total revenu increas
compar increas
global xgeva sale due higher unit demand higher net sell
total revenu increas
compar total revenu increas
compar
total revenu rest world increas
compar total revenu increas
compar
total revenu kyproli increas
compar total revenu increas
compar
total revenu increas compar
total revenu increas
compar
total revenu rest world increas
compar total revenu rest
world increas compar
total revenu parsabiv
total revenu
total revenu rest world
total revenu xgeva
increas
compar
total revenu
kyproli increas
compar
total revenu sensipar decreas
compar total revenu increas
compar
total revenu declin compar
total revenu increas
compar
total revenu rest world increas
compar total revenu increas
compar
decreas global sensipar sale due unfavor
chang inventori lower unit demand result shift
parsabiv increas global sensipar sale due
higher unit demand increas net sell price inventori
shift reimburs medicar part part
begin provid may order addit suppli
order ensur patient treatment interrupt
total revenu repatha increas
compar total revenu increas
compar
total revenu increas compar
total revenu increas
compar
total revenu rest world compar
total revenu compar
increas due higher unit demand off-set net
total revenu
sensipar decreas
compar
total revenu
repatha increas
compar
total revenu nplate increas
compar total revenu increas
compar
total revenu increas compar
total revenu increas
compar
total revenu rest world increas
compar total revenu increas
compar
total revenu blyncyto increas
compar total revenu increas
compar increas due
higher unit demand
total revenu increas compar
total revenu increas
compar
total revenu rest world increas
compar total revenu increas
compar
total revenu vectibix increas
compar total revenu increas
compar
total revenu increas compar
total revenu increas
compar
total revenu nplate
increas
compar
total revenu
blyncyto increas
compar
total revenu rest world decreas
compar total revenu increas
compar
total revenu decreas
compar total revenu declin
compar
total revenu declin compar
total revenu declin
compar
total revenu rest world decreas
compar total revenu declin
compar
total revenu enbrel decreas
compar total revenu declin
compar
total revenu declin
compar total revenu declin
compar
total revenu rest world declin
compar total revenu declin
compar
decreas enbrel sale due unfavor
chang inventori lower unit demand decreas enbrel
sale due lower unit demand declin net
total revenu
decreas
compar
total revenu enbrel
decreas
compar
total revenu neulasta increas
compar total revenu decreas
compar
total revenu increas
compar total revenu decreas
compar
total revenu rest world increas
compar total revenu decreas
compar
increas global neulasta sale due
increas net sell price favor chang inventori off-set
partial lower unit demand decreas global neulasta sale
due lower unit demand favor prior-period
chang account estim off-set partial increas net
total revenu epogen decreas
compar total revenu declin
compar
decreas sale due decreas net sell price due
contractu term negoti davita inc lower unit demand
total revenu aranesp decreas
compar total revenu declin
compar declin due
impact competit unit demand lower net sell price
total revenu
neulasta increas
compar
total revenu epogen
decreas
compar
announc ec
repatha label
adult establish
announc fda
approv aimovig
prevent treatment
migrain adult
total revenu declin compar
total revenu declin
compar
total revenu rest world declin
compar total revenu declin
compar
follow signific develop
affect compani busi
may june fda european commiss ec
respect approv new indic treatment
glucocorticoid-induc osteoporosi adult patient high risk
fractur approv base data phase studi
show patient glucocorticoid therapi receiv prolia
greater gain bone miner densiti compar receiv
activ compar risedron
juli announc resubmiss biolog licens
applic fda even investig monoclon
antibodi treatment osteoporosi postmenopaus women
high risk fractur
may announc fda approv aimovig
prevent treatment migrain adult collabor
novarti develop commerci aimovig
june announc ec grant full market
author blincyto base overal surviv data
phase tower studi adult patient philadelphia chromosome-
neg relaps refractori b-cell precursor acut lymphoblast
april announc committe medicin
product human use european medicin agenc adopt
posit opinion recommend label variat kyproli includ
final overal surviv data phase carfilzomib
lenalidomid dexamethason versu lenalidomid
dexamethason treatment patient relaps multipl
studi demonstr addit kyproli
lenalidomid dexamethason reduc risk death
versu lenalidomid dexamethason alon extend overal
surviv month patient relaps refractori multipl
june announc fda approv supplement
new drug applic add posit overal surviv data
phase studi prescrib inform kyproli
june present result phase arrow
random open-label phase studi subject relaps
refractori multipl myeloma receiv carfilzomib combin
carfilzomib dose studi once-weekli kyproli dose regimen
patient relaps refractori multipl myeloma
announc ec
author
announc fda
approv
applic add
data phase
studi
kyproli
announc receiv
letter fda
biolog licens
applic kanjinti
studi kyproli administ once-weekli
dexamethason achiev superior progression-fre surviv overal
respons rate compar safeti profil versu twice-weekli
kyproli dexamethason
may ec grant market author kanjinti
biosimilar candid herceptin treatment
metastat breast cancer earli breast cancer
posit metastat adenocarcinoma stomach gastroesophag
may announc receiv complet respons
letter fda biolog licens applic kanjinti
june announc result phase studi evalu
efficaci safeti biosimilar candid abp compar
remicad infliximab patient moderate-to-sever rheumatoid
arthriti result confirm noninferior compar infliximab
could rule superior base primari efficaci endpoint
may announc ec approv new indic
repatha label adult establish atherosclerot
cardiovascular diseas myocardi infarct stroke peripher arteri
diseas reduc cardiovascular risk lower low-dens lipoprotein
guidanc conclus
total revenu expect rang
non-gaap ep expect rang
non-gaap tax rate expect rang
deliv strong result due double-digit volum growth
newli launch product repatha kyproli prolia xgeva
strong sale outsid total revenu increas
total product revenu increas gaap
net incom increas ep increas
june announc ec grant full market
author blincyto may announc receiv
complet respons letter fda biolog licens applic
kanjinti launch aimovig
first cgrp inhibitor approv migrain prevent aimovig also
mark first entri new therapeut area neurosci
ytd stock perform roa roi roe
ttm basi respect remain confid
newer product launch well medicin advanc
pipelin enabl drive attract volume-driven growth global
long-term
newer product
launch well
pipelin
enabl drive
growth global
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
revenu growth ttm compar
ep growth ttm compar
net margin increas ttm compar
oper margin increas ttm compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth inc septemb
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale amgen inc septemb
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset amgen inc septemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item amgen inc septemb
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc net chang capit free inc septemb
price-to-earnings volatil past due volatil stock price price-to-earnings trail
current price-to-earnings
averag price-to-earnings expect forward price-to-earnings
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form robert anthoni brian sean david jonathan vanc institut holdersholdershar report outvaluevanguard group inc fmr capit research global primecap manag northern trust morgan america top mutual fund holdersholdersharesd report outvaluevanguard total stock market invest compani vanguard/primecap vanguard spdr etf capit world growth incom vanguard institut fund-institut capit incom builder growth fund america amcap competit
developmentseuropean commiss approv blincyto blinatumomab use pediatr patient philadelphia chromosome-neg relaps refractori b-cell precursor acut lymphoblast leukemiaaugust theeuropean commiss ec approv expand indic blincyto blinatumomab monotherapi treatment pediatr patient age one year older withphiladelphiachromosome-neg posit b-cell precursor acut lymphoblast leukemia refractori relaps receiv least two prior therapi relaps receiv prior allogen hematopoiet stem cell transplant approv base result phase studi open-label multicent single-arm trial evalu efficaci safeti blincyto pediatr patient relaps refractori b-cell precursor submit supplement new drug applic kyproli carfilzomib once-weekli combin dexamethasoneaugust announc submiss supplement new drug applic snda theu food drug administr fda expand prescrib inform kyproli carfilzomib includ once-weekli dose option combin dexamethason kd patient relaps refractori multipl myeloma snda base data phase trial demonstr kyproli administ once-weekli dexamethason once-weekli kd achiev superior progression-fre surviv overal respons rate orr compar safeti profil versu twice-weekli kyproli dexamethason twice-weekli kd cedars-sinai improv healthcar qualityjuli medic center announc partnership help support improv healthcar qualiti treatment multipl therapeut area could includ oncolog cardiovascular diseas osteoporosi migrain organ intend jointli undertak research project one therapeut area also plan focu project could achiev better clinic outcom experi patient satisfact propos initi project three-year agreement focu cancer therapi line cedars-sinai rank southern california largest provid oncolog servic leadership field partnership also plan evalu variou way help improv medic adher technolog healthcar solut novarti present new data demonstr long-term efficaci safeti toler aimovig erenumab-aoo patient chronic episod migrainejun announc result two open-label extens ole studi aimovig patient chronic episod migrain respect present scientif meet theamerican headach societi ah insan francisco result one-year studi chronic migrain patient reinforc establish safeti efficaci profil aimovig long-term use addit three-year interim analysi on-going five-year studi episod migrain patient longest run studi calcitonin gene-rel peptid cgrp therapi reinforc long-term safeti toler aimovig aimovig first onlyfda-approv therapi target cgrp pathway inc septemb
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
higher
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit inc septemb
consensu view analyst trend stock
forecast
compar
forward price-to-earnings
compar
valuat comparisonamgnindustri avg avgprice/earn yield avgfive-year growth forecast usdgrowth high day day day estim inc septemb
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr amgen inc septemb
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
stock price show upward trend quarter surg august
stock gave return period averag daili volum share trade
quarter
stock price show huge fluctuat past one year dip april
stock given return past rang stock
stock price show huge fluctuat past surg septemb
stock given return past
deliv strong quarterli result growth revenu product sale grew
growth due double-digit volum growth new recent launch product
maintain buy rate base perform expect launch upgrad
tp base price-to-earnings multipl adjust ep
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
